Abstract
Injection of amyloid-beta peptide (Aβ 1-42) into hippocampal and cortical regions of brain may have utility as an animal model of Alzheimers disease (AD) emphasizing the inflammatory component of disease pathology. This review summarizes recent evidence supporting the relevance of the peptide injection model to describe inflammatory conditions in AD brain. A wide spectrum of responses are considered from effects of Aβ 1-42 on animal behavior and cognitive performance to peptide actions at the cellular and molecular levels. In the latter case a particular focus is placed on inflammatory responses mediated by activated microglia. Specific pharmacological modulations of microglial signaling pathways and factors and how they shape patterns of inflammatory reactivity in peptide-injected brain are included. Overall, the considerations for the validity and limitations of Aβ 1-42 injection as an animal model for AD pathology are also discussed.
Keywords: Alzheimer's disease, amyloid-β peptide (Aβ1 - 4 2 ), Aβ1, –, 4 2 injection animal model, inflammatory reactivity, pharmacological modulations
Current Alzheimer Research
Title: Relevance of Aβ 1-42 Intrahippocampal Injection as An Animal Model of Inflamed Alzheimers Disease Brain
Volume: 5 Issue: 5
Author(s): James G. McLarnon and Jae K. Ryu
Affiliation:
Keywords: Alzheimer's disease, amyloid-β peptide (Aβ1 - 4 2 ), Aβ1, –, 4 2 injection animal model, inflammatory reactivity, pharmacological modulations
Abstract: Injection of amyloid-beta peptide (Aβ 1-42) into hippocampal and cortical regions of brain may have utility as an animal model of Alzheimers disease (AD) emphasizing the inflammatory component of disease pathology. This review summarizes recent evidence supporting the relevance of the peptide injection model to describe inflammatory conditions in AD brain. A wide spectrum of responses are considered from effects of Aβ 1-42 on animal behavior and cognitive performance to peptide actions at the cellular and molecular levels. In the latter case a particular focus is placed on inflammatory responses mediated by activated microglia. Specific pharmacological modulations of microglial signaling pathways and factors and how they shape patterns of inflammatory reactivity in peptide-injected brain are included. Overall, the considerations for the validity and limitations of Aβ 1-42 injection as an animal model for AD pathology are also discussed.
Export Options
About this article
Cite this article as:
McLarnon G. James and Ryu K. Jae, Relevance of Aβ 1-42 Intrahippocampal Injection as An Animal Model of Inflamed Alzheimers Disease Brain, Current Alzheimer Research 2008; 5 (5) . https://dx.doi.org/10.2174/156720508785908874
DOI https://dx.doi.org/10.2174/156720508785908874 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Sugars that Glow in the Dark: Fluorescent Tagged Glucose Bioprobes and their Facilitation of the Drug Discovery Process
Current Medicinal Chemistry Consciousness, Functional Networks and Delirium Screening
Current Aging Science Hydrogen Sulfide: A New Tool to Design and Develop Drugs
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Systems Biology Approaches and Metabolomics for Understanding Japanese Traditional Kampo Medicine
Current Pharmacogenomics and Personalized Medicine Butyrylcholinesterase as a Diagnostic and Therapeutic Target for Alzheimer’s Disease
Current Alzheimer Research Filling the Gaps in the Aβ Cascade Hypothesis of Alzheimers Disease
Current Alzheimer Research Transgenic Overproduction of Omega-3 Polyunsaturated Fatty Acids Provides Neuroprotection and Enhances Endogenous Neurogenesis After Stroke
Current Molecular Medicine Update on Alzheimer’s Disease Therapeutics
Reviews on Recent Clinical Trials Systemic Administration of Fluoro-Gold for the Histological Assessment of Vascular Structure, Integrity and Damage
Current Neurovascular Research Novelty in Inflammation and Immunomodulation in Migraine
Current Pharmaceutical Design Neuroprotective Effects of Citrus Fruit-Derived Flavonoids, Nobiletin and Tangeretin in Alzheimer's and Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Does Religiosity Protect Against Cognitive and Behavioral Decline in Alzheimers Dementia?
Current Alzheimer Research η-Secretase: Reduction of Amyloid Precursor Protein η-Site Cleavage in Alzheimers Disease
Current Alzheimer Research Clinical and Prognostic Implications of Cognitive Dysfunction and Depression in COPD
Current Respiratory Medicine Reviews Crocin Protects Against Beta-Amyloid Peptide-Induced Apoptosis in PC12 Cells Via the PI3 K Pathway
Current Molecular Pharmacology VIP in Neurological Diseases: More Than A Neuropeptide
Endocrine, Metabolic & Immune Disorders - Drug Targets Cardiovascular Toxicity of Cyclooxygenase Inhibitors and Promising Natur a l Substitutes
Current Pharmaceutical Design Aluminofluoride Complexes: Phosphate Analogues and a Hidden Hazard for Living Organisms
Current Inorganic Chemistry (Discontinued) Simvastatin and Other HMG-CoA Reductase Inhibitors on Brain Cholesterol Levels in Alzheimers Disease
Current Alzheimer Research Obstacles and Opportunities for Cholinergic Drug Development in the Treatment of Cognitive Disorders
Current Pharmaceutical Design